<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://allsci.com/news/approvals/bixlenvo-fda-approval-hiv-approves-gileads-for/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-28T14:22:33.786454Z</news:publication_date>
      <news:title>FDA approves Gilead&apos;s Bixlenvo to simplify complex HIV regimens</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/paxalisib-triple-negative-breast-cancer/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-28T08:09:20.713343Z</news:publication_date>
      <news:title>Kazia touts 100% clinical benefit rate for paxalisib in early-stage TNBC study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/combination-flu-vaccine-osivax-pairs-phase-ii/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-28T07:56:31.860607Z</news:publication_date>
      <news:title>Osivax pairs Phase II flu vaccine with GC Biopharma&apos;s marketed shot in combination deal</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/regulatory/fda-approves-covid-19-vaccines-2026-modernas/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-28T07:46:45.320373Z</news:publication_date>
      <news:title>FDA approves Moderna&apos;s updated 2026-2027 COVID-19 vaccines for high-risk and older adults</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/genentech-dualitybio-adc-collaboration-taps/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-28T07:39:44.492166Z</news:publication_date>
      <news:title>Genentech taps DualityBio&apos;s DUPAC platform for multi-program ADC collaboration</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/research/shingles-vaccine-cardiovascular-risk-recombinant/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-28T07:33:36.695576Z</news:publication_date>
      <news:title>Shingrix shows potential cardiovascular benefit in US natural experiment</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/regulatory/skyrizi-crohns-disease-ema-abbvie-seeks-approval/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-27T12:34:22.863778Z</news:publication_date>
      <news:title>AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn&apos;s disease</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/tezspire-eosinophilic-esophagitis-extends-tslp/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-27T11:56:34.451842Z</news:publication_date>
      <news:title>Amgen/AZ&apos;s Tezspire extends TSLP platform to eosinophilic esophagitis with Phase III win</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/gv101-rock2-inhibitor-chronic-graft-versus-host-disease/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-26T16:40:07.284481Z</news:publication_date>
      <news:title>Graviton/Beijing Tide’s GV101 posts 86% response rate in Phase Ib cGvHD study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/first-in-human-trials/tnfr2-agonist-atopic-dermatitis-trexbio-advances/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-26T16:30:49.163920Z</news:publication_date>
      <news:title>TRexBio’s TNFR2 agonist shows human proof-of-mechanism in Phase I</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/approvals/pancreatic-cancer-treatment-fda-approval/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-26T16:21:50.215360Z</news:publication_date>
      <news:title>Revolution lands first approval for RAS(ON) platform with Rasonque</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/regulatory/revtorpyk-pik3ca-breast-cancer-celcuity-seeks/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-26T14:39:57.122167Z</news:publication_date>
      <news:title>Celcuity seeks to expand Revtorpyk label to PIK3CA-mutant breast cancer after beating alpelisib</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/regulatory/ck0803-fda-fast-track-als-cellenkoss-treg-cell/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-26T14:32:26.133201Z</news:publication_date>
      <news:title>Cellenkos&apos;s Treg cell therapy CK0803 wins FDA fast track for ALS</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/approvals/rett-syndrome-treatment-european-commission/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-26T14:28:02.967034Z</news:publication_date>
      <news:title>EC approves Acadia&apos;s Daybu as first-ever Rett syndrome treatment in the EU</news:title>
    </news:news>
  </url>
</urlset>